Pharma Focus Asia

Yposkesi Plans to Construct Second Bioproduction Site in Europe


Yposkesi plans to open new bioproduction site with an investment of US$71 million (€58M).


The site features two additional production lines with numerous 1000L scale bioreactors. In addition, it also includes quality control lab resources, centralized warehouse, solutions and mountings preparation as well as drug substance production suites and storage.

The new facility will be the global resource for drug developers of biologics called ATMPs (Advanced Therapy Medicinal Products).

The production site will be one of the largest facilities in Europe, designed with an area covering 5,000m2 (50,000 ft²). Moreover, the new state-of-the-art facility, will double its production surface to 10,000m2 (100,000 ft²).

The site supposed to address the needs of shortage in manufacturing capacity for drug developers seeking to support advanced clinical trials and to commercialize new therapeutic drugs.

The construction of the project is expected to begin on May 25, 2021 and scheduled to be fully operational in 2023. The commercial facility will create approximately 80 new jobs.


TypeNew Construction
Budget$71M (€58M)
magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference